Late-Breaking Data Shows Abbott's MitraClip ™ is Cost Effective, Increases Life Expectancy and Improves Quality of Life

- New late-breaking data at TCT 2019 demonstrate that Abbott's MitraClip ™ is cost-effective for heart failure patients with significant secondary mitral regurgitation compared to guideline-directed medical therapy alone
Source: Abbott.com - Category: Pharmaceuticals Source Type: news